Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus cobimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAF V600-mutant advanced melanoma
NL-OMON47276Phase 3Recruiting
- Sponsor
- Roche
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma and cutaneous malignancy comparing Placebo + cobimetinib + vemurafenib with Atezolizumab + cobimetinib + vemurafenib (2 arms). Primary endpoint: Progression-free survival. Started Apr 2017; status: recruiting.
02
Drugs
atezolizumabcobimetinibvemurafenib
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON47276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47276.